about
Guidelines on the use of intravenous immune globulin for hematologic conditions.Anti-HPA-1b Mediated Posttransfusion Purpura: A Case Report.Guidance on platelet transfusion for patients with hypoproliferative thrombocytopenia.Anemia and blood transfusion practices in the critically ill: a prospective cohort review.Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal.Failure of prophylactic intravenous immunoglobulin to prevent sensitization to cryopreserved allograft tissue used in congenital cardiac surgery.Allogeneic blood transfusion reduction by risk-based protocol in total joint arthroplasty.Bedside to bench: The risk of bleeding with parenteral omega-3 lipid emulsion therapy.Reversal of dabigatran-associated major bleeding with activated prothrombin concentrate: A prospective cohort study.Vox Sanguinis International Forum on provision of granulocytes for transfusion and their clinical use: summary.ACP Journal Club. In critically ill adults, transfusion of fresh vs standard-issue red blood cells did not differ for 90-day mortality.Transfusion-related acute lung injury after transfusion of pooled immune globulin: a case report.Activated prothrombin complex concentrate for dabigatran-associated bleeding.Dabigatran assessment in patients with acute complications using routine coagulation assays.Flow cytometric detection of CD79a expression in T-cell acute lymphoblastic leukemiasGuidelines for the use of immunoglobulin therapy for primary immune deficiency and solid organ transplantation
P50
Q33374720-313D3598-D5D8-4F97-BFBD-C11C51C2F0B8Q33413091-F1480D0A-83AF-41CF-A5CC-31E4F12513F3Q33419477-5E0A8685-557B-4E05-9404-A71154EC64C8Q37748165-C7922AC7-2977-4932-9CE3-F70288F4DF6CQ38007409-DE07708E-FC45-4E69-AA65-7219C8550830Q40209116-95CB7D90-7620-4A40-B68D-A0182453BD71Q43184912-603628E7-7D35-4D5C-9BB1-3028998608DFQ43682496-A0BD084B-55E5-40C3-9220-E61F16948B43Q47233133-01B91AAC-AA8B-4961-8CB5-D1B4599EC387Q48349052-B4D8AD53-0962-438D-9ABB-51A6761D4FDAQ50439990-3BA26922-FEEE-49EB-BE17-A8F875ADB022Q51136107-44D5788E-1314-4172-9D03-7547EA6DF342Q53084350-015E4CA5-69BC-4EF6-AD62-9E162F13F96CQ53139417-658E02F2-16BC-4637-AD93-4182A4D286E5Q73940832-F1452B1D-0BD9-4529-A821-CF63934B398BQ84983549-19708980-D49A-4773-94AB-903331FEBEEB
P50
description
researcher ORCID ID = 0000-0002-2895-4805
@en
wetenschapper
@nl
name
Susan Nahirniak
@ast
Susan Nahirniak
@en
Susan Nahirniak
@es
Susan Nahirniak
@nl
type
label
Susan Nahirniak
@ast
Susan Nahirniak
@en
Susan Nahirniak
@es
Susan Nahirniak
@nl
prefLabel
Susan Nahirniak
@ast
Susan Nahirniak
@en
Susan Nahirniak
@es
Susan Nahirniak
@nl
P106
P21
P31
P496
0000-0002-2895-4805